Top 10 Global Pharma Seeks Treatment Leaders to Advance Patient Representation for a Phase II Cardiology Trial

When it comes to advancing patient representation in clinical trials, the challenge is finding healthcare providers (HCPs) with an inclusive patient population that are also willing and able to participate. A global top 10 pharma company recently asked H1 to help them identify HCPs for outreach related to their phase II trial on Atherosclerotic Cardiovascular Disease (ASCVD), a type of heart disease caused by consistent high LDL-C levels in the blood that lead to plaque buildup on artery walls.

With an industry leading KOL identification platform – HCP Universe, clinical trial intelligence solutions and strategic insights team, H1 took on this challenge with a tech-first, data-driven and cross-functional approach to narrow down potential HCPs and curate a list for trial outreach. Now, let’s take a look at how they did it.

Get the case study: Top 10 Global Pharma Seeks Treatment Leaders to Advance Patient Representation for a Phase II Cardiology Trial